NEW YORK (GenomeWeb News) – 23andMe today announced the expansion of its online study conducted with Genentech for the biotech firm's oncology drug Avastin (bevacizumab).

In a post on 23andMe's blog, the Mountain View, Calif.-based company said that its study with Genentech, called InVite, is now open to any patient in the US who used Avastin before 2013 for treatment of metastatic colorectal cancer, metastatic non-squamous non-small cell lung cancer, relapsed glioblastoma, metastatic renal cell carcinoma, or metastatic breast cancer.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers in China have generated mouse pups from same-sex parents, according to Scientific American.

Two research teams find a role for PIEZO2 in touch sensitivity after injury and inflammation.

The South China Morning Post reports that Hong Kong plans to add HK$20 billion (US$2.6 billion) to a research endowment.

In Science this week: open genetic genealogy databases can lead to the identification of individuals who have not sought testing, and more.

Oct
23
Sponsored by
PerkinElmer

This webinar will address a range of methods for optimizing small RNA library preparation.

Nov
05
Sponsored by
Sophia Genetics

With the Next Generation Sequencing (NGS), genomes sequencing has been democratized over the last decades with the detection of genomic alterations, thus replacing Sanger sequencing.

Nov
29
Sponsored by
Schott

This webinar will discuss how understanding the relative performance characteristics of glass and polymer substrates for in vitro diagnostic applications such as microarrays and microfluidics can help to optimize diagnostic performance.